日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Bleeding and thrombotic outcomes with oral anticoagulants in patients with inflammatory bowel disease and venous thromboembolism

口服抗凝剂治疗炎症性肠病合并静脉血栓栓塞患者的出血和血栓形成结局

期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2025017617
Dawwas, Ghadeer K; Cuker, Adam; Lewis, James D
炎症/感染
炎症
心血管
发表日期：2026
文献求助 收藏

Shifting obesity treatment paradigms: Trends of glucagon-like peptide-1 receptor agonists and bariatric surgery in the United States

肥胖症治疗模式的转变：美国胰高血糖素样肽-1受体激动剂和减肥手术的趋势

期刊:Diabetes Obesity & Metabolism
影响因子:5.7
doi:10.1111/dom.16600
Dawwas, Ghadeer K; Samuels, Jason M; Stein, C Michael
信号转导
肥胖
代谢
发表日期：2025
文献求助 收藏

Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease Without Mechanical Valves

直接口服抗凝剂与华法林在无机械瓣膜的房颤合并瓣膜性心脏病患者中的比较

期刊:Journal of the American Heart Association
影响因子:5.3
doi:10.1161/JAHA.124.035478
Dawwas, Ghadeer K; Lewis, James D; Cuker, Adam
心脏病
心血管
发表日期：2025
文献求助 收藏

Comparative effectiveness and safety of rivaroxaban with other oral anticoagulants in older adults with nonvalvular atrial fibrillation: population-based analysis in response to updated Beers Criteria

利伐沙班与其他口服抗凝剂在老年非瓣膜性房颤患者中的疗效和安全性比较：基于更新的Beers标准的人群分析

期刊:Journal of Thrombosis and Haemostasis
影响因子:5
doi:10.1016/j.jtha.2024.10.009
Dawwas, Ghadeer K; Cuker, Adam
发表日期：2025
文献求助 收藏

Multi-ancestry genome-wide and transcriptome-wide association analyses identified new risk loci and genes for inflammatory bowel disease

多种族基因组和转录组关联分析发现了炎症性肠病的新风险位点和基因

期刊:
影响因子:
doi:10.1101/2025.09.23.25336483
Lyu, Linshuoshuo; Li, Qing; Li, Chao; Dawwas, Ghadeer K; Chen, You; Tao, Ran; Liu, Qi; Wen, Wanqing; Shu, Xiao-Ou; Washington, Kay; Schwartz, David A; Zheng, Wei; Yin, Zhijun; Lau, Ken S; Guo, Xingyi
炎症/感染
炎症
发表日期：2025
文献求助 收藏

The Clinical Course of Bowel Urgency Severity Among Patients with Inflammatory Bowel Disease-A Real-World Study

炎症性肠病患者肠道急迫严重程度的临床过程——一项真实世界研究

期刊:Drugs-Real World Outcomes
影响因子:1.9
doi:10.1007/s40801-024-00434-1
Lewis, James D; Gibble, Theresa Hunter; Shan, Mingyang; Zhou, Xian; Naegeli, April N; Dawwas, Ghadeer K
炎症/感染
炎症
发表日期：2024
文献求助 收藏

Incidence, Prevalence, and Racial and Ethnic Distribution of Inflammatory Bowel Disease in the United States

美国炎症性肠病的发病率、患病率及种族和民族分布

期刊:Gastroenterology
影响因子:25.1
doi:10.1053/j.gastro.2023.07.003
Lewis, James D; Parlett, Lauren E; Jonsson Funk, Michele L; Brensinger, Colleen; Pate, Virginia; Wu, Qufei; Dawwas, Ghadeer K; Weiss, Alexandra; Constant, Brad D; McCauley, Maureen; Haynes, Kevin; Yang, Jeff Yufeng; Schaubel, Douglas E; Hurtado-Lorenzo, Andres; Kappelman, Michael David
炎症/感染
炎症
发表日期：2023
文献求助 收藏

Apixaban Versus Rivaroxaban in Patients With Atrial Fibrillation and Valvular Heart Disease : A Population-Based Study

阿哌沙班与利伐沙班治疗房颤合并瓣膜性心脏病患者的疗效比较：一项基于人群的研究

期刊:Annals of Internal Medicine
影响因子:15.2
doi:10.7326/M22-0318
Dawwas, Ghadeer K; Cuker, Adam; Barnes, Geoffrey D; Lewis, James D; Hennessy, Sean
心脏病
心血管
发表日期：2022
文献求助 收藏

Long-term Outcomes Following Multiply Recurrent Clostridioides difficile Infection and Fecal Microbiota Transplantation

多次复发性艰难梭菌感染和粪便微生物移植后的长期疗效

期刊:Clinical Gastroenterology and Hepatology
影响因子:12
doi:10.1016/j.cgh.2020.12.004
Dawwas, Ghadeer K; Brensinger, Colleen M; Vajravelu, Ravy K; Wu, Qufei; Kelly, Colleen R; Laine, Loren; Wu, Gary D; Lewis, James D
微生物学
炎症/感染
发表日期：2022
文献求助 收藏

Apixaban has superior effectiveness and safety compared to rivaroxaban in patients with commercial healthcare coverage: A population-based analysis in response to CVS 2022 formulary changes

在商业医疗保险覆盖的患者中，阿哌沙班的疗效和安全性优于利伐沙班：一项基于人群的分析，旨在应对CVS 2022年药品目录的变化。

期刊:American Journal of Hematology
影响因子:9.9
doi:10.1002/ajh.26494
Dawwas, Ghadeer K; Cuker, Adam; Connors, Jean Marie; Barnes, Geoffrey D
发表日期：2022
文献求助 收藏